Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.

William V TamborlaneDavid PolidoriDomenick ArgentiNicholas A Di Prospero

Published in: Pediatric diabetes (2017)

In pediatric T2D patients, canagliflozin 100 and 300 mg had PK and PD characteristics similar to those in adults with T2D, which is likely due to the relative maturity and increased body weight of youth affected with this disorder.

Keyphrases

body weight
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
physical activity
mental health
patient reported outcomes
patient reported